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Abstract
Background: Liver fibrosis progression is commonly found in patients with CHB. Liver biopsy is a gold standard for
identifying the extent of liver fibrosis, but has many draw-backs. It is essential to construct a noninvasive model to
predict the levels of risk for liver fibrosis. It would provide very useful information to help reduce the number of
liver biopsies of CHB patients.
Methods: 339 chronic hepatitis B patients with HBsAg-positive were investigated retrospectively, and divided at
random into 2 subsets with twice as many patients in the training set as in the validation set; 116 additional
patients were consequently enrolled in the study as the testing set. A three-layer artificial neural network was
developed using a Bayesian learning algorithm. Sensitivity and ROC analysis were performed to explain the
importance of input variables and the performance of the neural network.
Results: There were 329 patients without significant fibrosis and 126 with significant fibrosis in the study. All
markers except gender, HB, ALP and TP were found to be statistically significant factors associated with significant
fibrosis. The sensitivity analysis showed that the most important factors in the predictive model were age, AST,
platelet, and GGT, and the influence on the output variable among coal miners were 22.3-24.6%. The AUROC in 3
sets was 0.883, 0.884, and 0.920. In the testing set, for a decision threshold of 0.33, sensitivity and negative
predictive values were 100% and all CHB patients with significant fibrosis would be identified.
Conclusions: The artificial neural network model based on routine and serum markers would predict the risk for
liver fibrosis with a high accuracy. 47.4% of CHB patients at a decision threshold of 0.33 would be free of liver
biopsy and wouldn’t be missed.
Background
Approximately 350 million people worldwide are
chronically infected with hepatitis B virus (HBV), espe-
cially in many developing countries in Asia[1-3]. Liver
fibrosis progression is commonly found in patients with
chronic hepatitis B (CHB). Up to 40% of CHB patients
will develop complications of liver cirrhosis and hepato-
cellular carcinoma (HCC)[4]. Patients with significant
fibrosis or cirrhosis should be considered for antiviral
therapy, which can potentially reverse cirrhosis and
reduce complications[5-7].
Currently, liver biopsy, a widely used gold standard for
the examination of the extent of liver fibrosis and HCC
in patients with CHB, has many draw-backs, such as
pneumothorax, pain, hemorrhage, or puncture of other
viscera[8-10]. In addition, sampling error leads to only
65% accuracy in liver biopsy specimens[11]. Therefore,
there is an increasing demand for noninvasive predictive
models of liver fibrosis. Those methods could predict
the risk probability of liver fibrosis and identify CHB
patients at high risk for liver fibrosis. If we only perform
liver biopsy on CHB patients at high risk for liver fibro-
sis, the number of liver biopsies would be reduced. In
the past few years, noninvasive biochemical markers of
liver fibrosis which could respond of the chronically
injured liver had made considerable progression[12-14].
Multiple algorithms based on a combination of fairly
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[15-17]. However, most of them required non-routine
laboratory assays or used complex and patented models
so that their regular use was limited. In fact, the true
usefulness of any indices or models for application to
clinical settings should be the easiness of the procedure
and analytical simplicity, so that the results can be com-
pared between laboratories for a long period[18].
The complete blood count and liver function are rou-
tine tests on CHB patients with hepatitis B surface anti-
gen (HBsAg-positive) in the clinical treatment. It is easy
to measure those markers with low cost in some labora-
tories, even in the Community Hospitals. Moreover, the
artificial neural network (ANN) is potentially more suc-
cessful than a traditional statistical model in predicting
clinical outcome [19,20]. It can build nonlinear statisti-
cal models through learning examples and has been
widely applied to predict, diagnose, and classify disease
in many fields [21,22]. In our study, we designed a
neural network which used a Bayesian learning algo-
rithm by introducing probabilistic treatment of the
Bayesian inference technique. It can overcome some dif-
ficult problems, such as local trapping, over-fitting, and
overtime in training. Also, it is proposed to have signifi-
cant advantages over the conventional neural network
approach [23].
The present study was performed on HBsAg-positive
patients. An artificial neural network model based on
routine and serum markers was constructed to predict
the risk for liver fibrosis. The objective of this study was
to determine the feasibility of these indices of routine
and serum markers to predict the risk for liver fibrosis.
Furthermore, we aimed to similarly validate the prob-
ability value in order to identify the risk for liver fibrosis
on CHB patients and classify high risk groups.
Methods
Patients
In April 2008, all HBsAg-positive in-patients who had
liver biopsy between January 2006 and March 2008 were
retrospectively investigated at the Hospital of Infectious
Diseases. Only patients without the following conditions
were included for the study: presence of other causes of
liver disease such as chronic hepatitis C (CHC), or hepa-
titis E (HE), etc., acute hepatitis, hepatocellular carci-
noma, prior liver transplantation, insufficient liver tissue
for staging of fibrosis, and incomplete data on complete
blood count or some serum markers of fibrosis. Addi-
tionally, patients without routine and serum markers
prior to drug treatment were also excluded. Within a
week of liver biopsy, those markers were recorded. If
more than one set of laboratory results were available,
the set of results closest to the time of biopsy were
used. Later, additional in-patients who met the
aforementioned criteria were consequently enrolled in
the study from April 2008 to July 2009.
The enrolled patients were informed all procedures
which conformed to the Helsinki Declaration. The study
procedures were also approved by the Ethics Committee
of the Infectious Diseases Hospital of Shenyang. The
verbal informed consent for all patients was provided.
Laboratory tests
Clinical chemistry tests were performed using 7150
Analyzer (Hitachi, Japan), and the complete blood count
were measured on Hematology Analyzer (Beckman
Coulter 5diff, U.S.A.).
Liver biopsy histology
Liver biopsy was performed by automatic fare cut biopsy
needle. Length and width of each sample were at least
10 mm and 1 mm, respectively. Liver sample of patients
who were enrolled since April 2008 would contain 2 or
more portal spaces. A single pathologist who had no
clinical information of patients evaluated all biopsy
results. The level of fibrosis was measured according to
the METAVIR system, which had previously been
applied in other reports on CHB[24,25]. Fibrosis was
staged from F0 to F4: F0, no fibrosis; F1, portal fibrosis
without septa; F2, few septa; F3, numerous septa with-
out cirrhosis; and F4, cirrhosis. Generally, significant
fibrosis was defined by F2, F3, or F4 stages; whereas F0
or F1 was considered as insignificant fibrosis.
Statistical analysis
All statistical analysis was performed using MATLAB
Neural Network Toolbox (2006) and SPSS Version 11.5
(SPSS, Inc, Chicago, IL). Data are reported as median
(minimum-maximum) unless otherwise stated. The rela-
tionship between variables and the presence of signifi-
cant fibrosis was assessed. The Mann-Whitney U Test,
or Kruskal-Wallis Test was used for continuous vari-
ables when appropriate. The Chi-square test was used
for categorical variables, and Fisher’se x a c tt e s tw h e n
appropriate. Those variables found to be strongly corre-
lated to the presence of significant fibrosis were used to
build the ANN.
Development of the neural network
Patients between January 2 0 0 6a n dM a r c h2 0 0 8w e r e
randomly divided into 2 subsets: training set and valida-
tion set, with twice as many patients in training set as in
validation set. Patients since April 2008 formed the test-
ing set. The three-layer neural network model was built
and trained using a Bayesian learning algorithm, which
had 1 output neuron (0, insignificant fibrosis; 1, signifi-
cant fibrosis). To determine the optimal number of neu-
rons in the intermediate layer, we randomly split all
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of neurons, we trained the network on all but one sub-
set, and tested it on the remaining one. We started from
6 neurons, and gradually increased the number of neu-
rons. When there were more than 13 neurons, the per-
formance of the trained neural network on output
sample in the testing set began to deteriorate. Hence,
the intermediate layer had 13 neurons in the current
neural network model. The number of training epochs
was set to 300, the learning rate was 0.05, and the train-
ing goal was set at 0.001.
As the neural network can be overtrained to recognize
specific cases in the training set and result in good per-
formance in the training set but not in the testing set,
the validation set was used to decide when to stop train-
ing in order to minimize the potential bias.
Sensitivity analysis
Neural network models have been long criticized for
being black box solutions primarily because of their
inability to generate interpretable parameters for each
input variable. To mitigate this problem, sensitivity ana-
lysis was adapted to explain their inference mechanism
[26]. In our study, each input variable to the network
varied between the mean ± standard deviation, while all
others were fixed at their respective means, and the cor-
responding change was recorded as a percentage devia-
tion in the output. It could help illustrate the effect of
changing a single input variable on the network output.
ROC curves
The receive operating characteristic (ROC) methodology
is a computational methodology which has a very
important connection to the neural network applied to
classification applications[27]. An important feature of
the ROC curves is that they readily incorporate preva-
lence and misclassification cost factors in decision-mak-
ing. In our study, the predictive accuracies of the neural
network were tested by measuring the area under the
ROC (AUROC). The optimal cutoff value to predict the
absence or presence of significant fibrosis was chosen.
Diagnostic accuracy was evaluated by calculating sensi-
tivity, specificity, positive and negative predictive values
(PPV and NPV), and Youden’s index.
Results
Patients characteristics
From January 2006 to March 2008, 396 patients who
showed evidence of HBsAg-positive and liver biopsy
were investigated. Among them, 57 were excluded from
this study because of the following reasons: 24 had HCV
or HIV co-infection, 4 had acute hepatitis, 7 had hepa-
tocellular carcinoma, and 22 lacked complete data on
laboratory tests. The demographic and clinical
characteristics were similar between those 57 excluded
patients and the rest of 339 patients fulfilling the entry
criteria. From April 2008, 116 CHB patients were con-
sidered for enrollment. So, a total of 455 patients were
included in this study in the end. Of overall subjects,
174 (38.2%) had no fibrosis (F0), 155 (34.1%) had portal
fibrosis (F1), 70 (15.4%) had septal fibrosis (F2), 47
(10.3%) had numerous septa (F3), and 9 (2.0%) had cir-
rhosis (F4). Their mean age was 33.9 ± 11.7 years; 289
(63.5%) were male, and 166 (36.5%) were female. Table
1 shows the comparison between patients with and
without significant fibrosis. All markers, except for gen-
der, hematoglobin (Hb), alkaline phosphatase (ALP) and
total protein (TP), were found to be statistically signifi-
cant factors associated with significant fibrosis, and were
used to initially construct the artificial neural network.
There were 226 subjects in the training set; 113 subjects
in the validation set; 116 ubjects in the testing set. The
variables used to construct the artificial neural network
were compared in three sets (Table 2). These markers
didn’t appear to be statistically significant.
Sensitivity analysis
The sensitivity analysis of 10 variables was outlined in
Figure 1. The value shown for each input variable is a
measure of its relative importance, with 0 representing a
variable that has no effect on the prediction and 1
representing a variable that completely dominates the
prediction. The horizontal axis is the input variables; the
vertical axis is the percent change on the output vari-
able. The most important factors in the predictive
model were age, aspartate aminotransferase (AST), pla-
telet, and g-glutamyltransferase (GGT), and the influ-
ence on the output variance among CHB patients were
24.6%, 23.8%, 23.7% and 22.3%, respectively.
Accuracy of the ROC curves
The performance of the neural network in predicting sig-
nificant fibrosis in three sets was high, and the AUROC
was as follows: 0.883 (in the training set), 0.884 (in the
validation set), and 0.920 (in the testing set; Figure 2).
Sensitivity, specificity, positive and negative predictive
values at different cutoff points in the testing set were
shown in Table 3. For a decision threshold of 0.33, sensi-
tivity and negative predictive values were 100%, which
indicated that this model could predict insignificant fibro-
sis with the highest accuracy. This procedure would have
correctly identified 47.4% of CHB patients without signifi-
cant fibrosis, who needn’t proceed with liver biopsy.
Discussion
Liver fibrosis is characterized by the accumulation of an
extracellular matrix (ECM), which distorts the hepatic
architecture. Liver fibrosis progression could commonly
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Variables Patients without significant fibrosis (F0-1), n =
329
Patients with significant fibrosis (F2-4), n =
126
c
2
value
P
Age 29(16-60) 40(17-75) 52.21 <
0.0001
Gender(M/F) 215/114 74/52 1.723 0.189
WBC(10
9/L) 5.3(2.3-12.2) 4.5(1.3-18.1) 14.51 <
0.0001
RBC(10
12/L) 4.8(3.5-4.0) 4.5(2.6-5.7) 9.47 0.002
Hb(g/L) 145(87-173) 141(85-167) 1.79 0.174
Platelet(10
9/L) 184(46-350) 136(13-246) 80.24 <
0.0001
ALT(U/L) 72.0(6-471) 174.1(11-536) 11.37 < 0.001
AST(U/L) 15.2(11-341) 63.4(11-413) 28.43 <
0.0001
GGT(u/L) 24.9(6-473) 66.5(8-327) 62.14 <
0.0001
ALP(u/L) 106(7-219) 117(19-307) 2.78 0.099
ChE(u/L) 8054(70-20427) 6617(50-12648) 41.28 <
0.0001
TP(g/L) 72.3(49-88.4) 72.1(40-88.3) 0.442 0.501
Alb(g/L) 45.4(11.6-47.0) 43.2(10.9-52.6) 18.14 <
0.0001
TBIL(μmol/L) 13.4(3-138) 15.3(5.5-216) 11.03 <
0.0001
Length of liver biopsy
(mm)
14(10-21) 12(11-19) 1.290 0.256
Number of liver biopsy 2.0(1.0-4.0) 2.5(1.0-5.0) 1.621 0.197
Table 2 Comparing input and output variables in three sets
Variables Patients in the training set, n = 226 Patients in the validation set, n = 113 Patients in the testing set, n = 116 c
2(p)
Age(years) 30(16-62) 35(16-75) 32(16-74) 1.741
(0.419)
WBC(10
9/L) 5.4(1.3-18.1) 5.5(2.5-16.8) 5.4(3.0-11) 0.231
(0.891)
RBC(10
12/L) 4.7(2.6-4.0) 4.7(3.6-5.7) 4.6(3.7-5.6) 0.310
(0.856)
Platelet(10
9/
L)
165(53-246) 170(13-350) 185(46-345) 4.965
(0.083)
ALT(U/L) 87(16-471) 80(11-536) 72(6-507) 2.475
(0.290)
AST(U/L) 48(11-413) 42.5(15-375) 39(11-361) 1.264
(0.531)
GGT(U/L) 29(6-421) 33(6-288) 34(10-473) 3.247
(0.197)
ChE(U/L) 8402(50-20427) 7674(145-11374) 7258(360-12648) 3.051
(0.217)
Alb(g/L) 44.8(10.9-47.0) 44.2(11.8-50.7) 44.1(31.3-52.6) 0.412
(0.814)
TBIL(μmol/L) 14.1(3.6-216) 15.3(3-196) 13.2(3- 134) 3.650
(0.161)
Fibrosis
F(0-1)/F(2-4)
166/60 83/30 80/36 0.657
(0.720)
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sive period of time during which liver biochemical
indices are found to be predominately or even persis-
tently abnormal[28]. Due to the limitation of liver
biopsy, noninvasive evaluation of liver fibrosis is thus of
great clinical interests in order to assess the risk for
liver fibrosis dynamically, or identify and monitor the
patients who should be considered antiviral or other
types of therapy.
Age, platelet, AST, ALT, GGT, etc., as routine bio-
chemical markers, had been well known predictors of
significant liver fibrosis[14,29,30]. In the present study,
based on common biochemical parameters including
routine and serum markers, we constructed a three-
layer neural network which extended a back-propagation
learning algorithm by introducing probabilistic treat-
ment of the Bayesian inference technique for the synap-
tic weight[31]. Results of sensitivity analysis showed the
importance of various predictors. As could be seen, the
most important variables influencing the prediction of
significant liver fibrosis were age, AST, platelet and
GGT. These results were consistent with some of the
earlier studies[14,16]. Sensitivity analysis showed that
the neural network using Bayesian approaches could
achieve its predictive purpose.
As demonstrated by ROC curves, the predictive accu-
racy of the artificial neural network was reasonably high
in the training, validation, and testing sets. The AUROC
were 0.883, 0.884 and 0.920, respectively. In view with
some noninvasive parameters directly or indirectly
related to fibrogenesis, the most prevalent are the
Fibrotest and the Actitest for necro-inflammator activity
[32]. They are based on GGT, TBIL, haptoglobin, a2-
macroglobulin, apolipoprotein A1, and for the Actitest
additionally on ALT[33]. Previous studies on Fibrotest
and Actitest have been validated with the ranges of the
AUROC of 0.75- 0.89 in CHB patients[14,25,32,34].
Although the two indices could provide better predictive
values according to different criteria, they were calcu-
lated with a patented and complicated algorithm, and it
Figure 1 Sensitivity analysis of input variables. The horizontal axis is the input variables; the vertical axis is the percent change on the output
variable. The value shown for each input variable is a measure of its relative importance, with 0 representing a variable that has no effect on the
prediction and 1 representing a variable that completely dominates the prediction.
Figure 2 ROC curve of the neural network output in three sets. (a) In the training set(Cutoff = 0.415, AUROC = 0.883); (b) In the validation
set(Cutoff = 0.421, AUROC = 0.884); (c) In the testing set(Cutoff = 0.418, AUROC = 0.920)
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states of liver fibrosis.
Hui AY constructed and validated a multivariate logis-
tic regression model using body mass index, platelet,
Alb, and TBIL level to predict advanced fibrosis, and
the AUROC were 0.765-0.803[17]. Zeng MD also con-
structed a scoring system with forward logistic regres-
sion, which was expressed by the following formula[16]:
-13.995 + 3.22l g(a2-macroglobulin)+ 3.096 lg(age) +
2.254 lg(GGT) + 2.437 lg(HA). The AUROC of this
model in the training and validation groups were 0.84
and 0.77, respectively. The logistic regression, a general-
ized linear model used for binomial regression, is used
for prediction of the probability of occurrence of an
event by fitting data to a logistic curve. The artificial
neural networks, a non-linear statistical data modeling
tool, can be used to model complex relationships
between inputs and outputs. Therefore, the present
study provided evidence that the three-layer neural net-
work model based on routine and serum markers was
superior to other indices or models for identification of
individual with or without significant fibrosis.
In our study, there were 126 patients with significant
liver fibrosis, which only accounted for 27.7% of 455
CHB patients with liver biopsy. In other words, 329
(72.3%) patients without significant liver fibrosis had
undergone liver biopsy, and they could bear the
damages from such an invasive procedure. From a more
practical point of view, we wanted to reduce the number
of liver biopsy procedures and also identify all CHB
patients with significant fibrosis. Therefore, our study
evaluated the influence of the different cutoff points on
the accuracy of ROC. When we chose a high cutoff
point, the number of CHB patients at high risk for sig-
nificant liver fibrosis was few, and also fewer patients
needed further liver biopsy or other examinations. But,
there was a low sensitivity and many CHB patients with
significant liver fibrosis could be missed. The purpose of
predicting the state of liver fibrosis is to identify CHB
patients with significant liver fibrosis or at high risk for
liver fibrogenesis to prevent them from further liver
fibrogenesis. Thus, we should choose a lower cutoff
point to improve the sensitivity, and to reduce the num-
ber of missed CHB patients at high risk for liver fibro-
genesis. So, we considered a probability value of 0.33 as
a cutoff value. CHB patients with a probability value >
0.33 were considered with significant liver fibrosis or at
high risk for liver fibrogenesis. In our study, all CHB
patients with significant liver fibrosis would be identi-
fied. 47.4% (55/116) of the CHB patients would be free
of liver biopsy and also wouldn’t be missed.
Limitations of the study
Our study was conducted in a specialized hospital for
infectious diseases. All individuals investigated were in-
patients, therefore not a completely random sample of
all CHB patients. However, owing to the limitation of
liver biopsy, we thought that the predictive model in
this study might be applied to identify the risk of liver
fibrosis as some studies showed [35].
The accuracy of a test could vary with the definition
of the target condition[36]. In our study, the occurrence
of F2, F3, or F4 was considered as significant fibrosis so
that the prevalence of significant fibrosis was relatively
low, which could affect the diagnostic accuracy of the
model by AUROC. The DANA (difference of prevalence
of advanced and nonadvanced fibrosis stages) was used
for the standardization of AUROC of fibrosis marker or
model[37]. But comparing with other studies
[14,16,17,25,32], we didn’t correct the AUROC by the
DANA.
Conclusions
The study highlighted the construction and assessment
of an artificial neural network for identifying the risk for
liver fibrosis. Age, platelet, AST, ALT, GGT, etc., as the
input variables of the artificial neural network model,
were widely available. The results of our study showed
that the three-layer artificial neural networks could
effectively identify the risk for liver fibrosis in CHB
patients with positive HBsAg. It could improve patient
compliance, and reduce the need for liver biopsy
required prior to antiviral or other types of therapy.
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Table 3 ROC analysis of artificial neural network output
at different cutoff points in the testing set
Cutoff
point
Sensitivity
%
Specificity
%
PPV
%
NPV
%
Youden Index
%
0.33 100.0 68.7 59.0 100.0 68.7
0.35 94.4 75.0 63.0 96.8 69.4
0.40 91.7 80.0 65.3 94.0 71.7
0.45 83.3 85.0 71.4 91.9 68.3
0.50 66.7 88.7 72.7 85.5 47.1
0.55 55.5 92.5 76.9 82.2 44.2
0.60 44.4 96.2 83.3 78.6 42.3
0.70 36.1 100.0 100.0 77.7 36.1
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